---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015779"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:36:01.425117+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Q3 net loss $2.1M; expands DNAbilize into obesity; cash $0.6M

## Summary
- Net loss of $2.1M ($0.70 per share) vs $3.2M ($6.36) in Q3 2023; R&D expense down to $1.3M from $2.3M.
- Cash of $0.6M as of Sept 30, 2024 (Dec 31, 2023: $1.1M); operating cash burn $7.7M YTD 2024.
- Initiated BP1001-A obesity program in October, first non-oncology application of DNAbilize technology targeting Grb2 insulin resistance.
- Completed enrollment for third dose cohort of BP1002 Phase 1/1b trial in venetoclax-resistant AML patients ahead of schedule.
- Closed $4.0M private placement in October: 4.6M shares and warrants at $0.87 per unit.

## SEC filing metadata
- accession: 0001558370-24-015779
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024015779/0001558370-24-015779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024015779/bpth-20241115x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015779
- JSON: https://secwatch.observer/filing/0001558370-24-015779.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.